



1645

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

077

In re Application of:

Alessio FASANO et al

Conf. No.: 8086

Appln. No.: 09/786,319

Group Art Unit: 1645

Filed: March 2, 2001

Examiner: Unknown

For: METHOD OF USING ZOT OR ZONULIN TO INHIBIT LYMPHOCYTE
PROLIFERATION IN AN ANTIGEN-SPECIFIC MANNER

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAY 15 2002

TECH CENTER 1600/2900

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) (substitute for Form PTO-1449) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, along with the Supplementary Partial European Search Report dated March 21, 2002, is submitted herewith.

The present Information Disclosure Statement is being filed after three months from the application's filing date for an application other than a Continued Prosecution Application (CPA) under §1.53(d), and before the mailing date of the first Office Action on the merits. Therefore, no Statement under

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 09/786,319

37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Gordon Kit

Registration No. 30,764

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: May 13, 2002



1645
PATENT APPLICATION *PH*

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEP 20 2001

In re Application of:

ALESSIO FASANO et al

Conf. No.: 8086

TECH CENTER 1600/2900

Appln. No.: 09/786,319

Group Art Unit: 1645

Filed: May 3, 2001

Examiner: Unknown

For: METHOD OF USING ZOT OR ZONULIN TO
INHIBIT LYMPHOCYTE PROLIFERATION
IN AN ANTIGEN-SPECIFIC MANNER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 which the Examiner may deem relevant to patentability of the claims of the above-identified application.

A copy of each of the listed documents are submitted herewith.

The present Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, therefore no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
U.S. Appln. No. 09/786,319

not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Gordon Kit
Registration No. 30,764

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: September 18, 2001